Six Questions For Janssen Pharma Chairman Paul Stoffels
This article was originally published in The Pink Sheet Daily
Executive Summary
Amid increasing competition, the need is to be the best in collaboration with academics, and not to rely on a single regulatory agency amid regulatory delays in China, stresses Johnson & Johnson senior executive Paul Stoffels in a wide-ranging exclusive interview with PharmAsia News.
You may also be interested in...
Backing New Index Fund, GSK, J&J Buy Into Asset-Centric Vision Of Biotech Future
Index Life VI is the first life-sciences-only fund for Index; GSK’s Moncef Slaoui and J&J’s Paul Stoffels are on scientific advisory board.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.